no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
1 |
Acknowledgements
|
|
|
|
19 |
S4 |
p. iv4-iv5 |
article |
2 |
aggressive lymphoma
|
|
|
|
19 |
S4 |
p. iv141-iv152 |
article |
3 |
aggressive lymphoma
|
|
|
|
19 |
S4 |
p. iv216-iv222 |
article |
4 |
amgen
|
|
|
|
19 |
S4 |
p. iv257-iv258 |
article |
5 |
Amyloidosis: is a cure possible?
|
Merlini, G. |
|
|
19 |
S4 |
p. iv63-iv66 |
article |
6 |
author index
|
|
|
|
19 |
S4 |
p. iv277-iv291 |
article |
7 |
Autoimmune disorders and lymphoma
|
Caligaris-Cappio, F. |
|
|
19 |
S4 |
p. iv31-iv34 |
article |
8 |
Bayer Schering Pharma
|
|
|
|
19 |
S4 |
p. iv276 |
article |
9 |
bayer schering pharma
|
|
|
|
19 |
S4 |
p. iv270 |
article |
10 |
Bing Center for Waldenström's macroglobulinemia update on plasma cell disorders
|
|
|
|
19 |
S4 |
p. iv267-iv269 |
article |
11 |
biogen idec oncology
|
|
|
|
19 |
S4 |
p. iv264 |
article |
12 |
Burkitt lymphoma versus diffuse large B-cell lymphoma
|
Rosenwald, A. |
|
|
19 |
S4 |
p. iv67-iv69 |
article |
13 |
celgene
|
|
|
|
19 |
S4 |
p. iv271-iv272 |
article |
14 |
celgene
|
|
|
|
19 |
S4 |
p. iv254 |
article |
15 |
cephalon oncology
|
|
|
|
19 |
S4 |
p. iv255-iv256 |
article |
16 |
CLL
|
|
|
|
19 |
S4 |
p. iv204-iv206 |
article |
17 |
CLL
|
|
|
|
19 |
S4 |
p. iv192-iv196 |
article |
18 |
Conference Schedule
|
|
|
|
19 |
S4 |
p. iv9-iv29 |
article |
19 |
controversy I: do we need radiotherapy in early HL?
|
|
|
|
19 |
S4 |
p. iv82 |
article |
20 |
controversy II: has PET changed the approach to lymphoma patients?
|
|
|
|
19 |
S4 |
p. iv122 |
article |
21 |
Current treatment standards and future strategies in mantle cell lymphoma
|
Dreyling, M. |
|
|
19 |
S4 |
p. iv41-iv44 |
article |
22 |
Editorial Board
|
|
|
|
19 |
S4 |
p. i, iii |
article |
23 |
epidemiology
|
|
|
|
19 |
S4 |
p. iv197-iv198 |
article |
24 |
extranodal lymphoma
|
|
|
|
19 |
S4 |
p. iv223-iv229 |
article |
25 |
extranodal lymphoma
|
|
|
|
19 |
S4 |
p. iv186-iv191 |
article |
26 |
Extranodal lymphoma: a reappraisal
|
Zucca, E. |
|
|
19 |
S4 |
p. iv77-iv80 |
article |
27 |
f. hoffmann la roche ltd giving your patients the best chance of cure
|
|
|
|
19 |
S4 |
p. iv261-iv263 |
article |
28 |
“focus on…” session: CLL
|
|
|
|
19 |
S4 |
p. iv89-iv90 |
article |
29 |
“focus on…” session: lymphoma biology
|
|
|
|
19 |
S4 |
p. iv125-iv126 |
article |
30 |
“focus on…” session: new treatments modalities
|
|
|
|
19 |
S4 |
p. iv115-iv116 |
article |
31 |
“focus on….” session: PET
|
|
|
|
19 |
S4 |
p. iv123-iv124 |
article |
32 |
“focus on…” session: primary mediastinal and other extranodal lymphoma
|
|
|
|
19 |
S4 |
p. iv95-iv96 |
article |
33 |
“focus on…” session: profiling and prognosis
|
|
|
|
19 |
S4 |
p. iv93-iv94 |
article |
34 |
“focus on…” session: radioimmunotherapy
|
|
|
|
19 |
S4 |
p. iv87-iv88 |
article |
35 |
“focus on…” session: T-cell
|
|
|
|
19 |
S4 |
p. iv113-iv114 |
article |
36 |
“focus on…” session: transformation
|
|
|
|
19 |
S4 |
p. iv111-iv112 |
article |
37 |
“focus on…” session: transplantation
|
|
|
|
19 |
S4 |
p. iv91-iv92 |
article |
38 |
Genentech BioOncology
|
|
|
|
19 |
S4 |
p. iv273-iv274 |
article |
39 |
glaxosmithkline
|
|
|
|
19 |
S4 |
p. iv259-iv260 |
article |
40 |
Hodgkin lymphoma
|
|
|
|
19 |
S4 |
p. iv233-iv237 |
article |
41 |
Hodgkin's lymphoma
|
|
|
|
19 |
S4 |
p. iv133-iv137 |
article |
42 |
imaging
|
|
|
|
19 |
S4 |
p. iv249-iv251 |
article |
43 |
indolent lymphoma
|
|
|
|
19 |
S4 |
p. iv176-iv185 |
article |
44 |
Indolent NHL
|
|
|
|
19 |
S4 |
p. iv207-iv211 |
article |
45 |
key note lectures
|
|
|
|
19 |
S4 |
p. iv81 |
article |
46 |
lymphoma biology
|
|
|
|
19 |
S4 |
p. iv199-iv203 |
article |
47 |
lymphoma biology
|
|
|
|
19 |
S4 |
p. iv166-iv170 |
article |
48 |
Maintenance treatment in multiple myeloma
|
Harousseau, J.L. |
|
|
19 |
S4 |
p. iv54-iv55 |
article |
49 |
mantle cell lymphoma
|
|
|
|
19 |
S4 |
p. iv172-iv175 |
article |
50 |
mantle cell lymphoma
|
|
|
|
19 |
S4 |
p. iv212-iv215 |
article |
51 |
MicroRNAs and lymphomas
|
|
|
|
19 |
S4 |
p. iv39-iv40 |
article |
52 |
Millennium Pharmaceuticals Ortho Biotech, a division of Janssen-Cilag emerging therapies for relapsed and refractory lymphoid neoplasms
|
|
|
|
19 |
S4 |
p. iv275 |
article |
53 |
miscellaneous
|
|
|
|
19 |
S4 |
p. iv252-iv253 |
article |
54 |
multiple myeloma
|
|
|
|
19 |
S4 |
p. iv171 |
article |
55 |
multiple myeloma/WM
|
|
|
|
19 |
S4 |
p. iv238 |
article |
56 |
mundipharma
|
|
|
|
19 |
S4 |
p. iv265 |
article |
57 |
New monoclonal antibodies for non-Hodgkin's lymphoma
|
Leonard, J.P. |
|
|
19 |
S4 |
p. iv60-iv62 |
article |
58 |
New response criteria for lymphomas in clinical trials
|
Cheson, B.D. |
|
|
19 |
S4 |
p. iv35-iv38 |
article |
59 |
New targets for lymphoma treatment
|
Johnson, P.W.M. |
|
|
19 |
S4 |
p. iv56-iv59 |
article |
60 |
new treatment modalities
|
|
|
|
19 |
S4 |
p. iv243 |
article |
61 |
new treatment modalities
|
|
|
|
19 |
S4 |
p. iv158-iv163 |
article |
62 |
Non-MALT marginal zone lymphomas
|
Thieblemont, C. |
|
|
19 |
S4 |
p. iv70-iv73 |
article |
63 |
pediatric lymphoma
|
|
|
|
19 |
S4 |
p. iv138-iv140 |
article |
64 |
pediatrics
|
|
|
|
19 |
S4 |
p. iv248 |
article |
65 |
poster session II, Friday 6 June (Marquee Parlo Ciani) pathology
|
|
|
|
19 |
S4 |
p. iv164-iv165 |
article |
66 |
poster session I Thursday 5 June (Marquee Parco Ciani) epidemiology
|
|
|
|
19 |
S4 |
p. iv131-iv132 |
article |
67 |
Prognostic factors in chronic lymphocytic leukemia
|
Hallek, M. |
|
|
19 |
S4 |
p. iv51-iv53 |
article |
68 |
Radiotherapy in non-Hodgkin lymphomas
|
Gospodarowicz, M. |
|
|
19 |
S4 |
p. iv47-iv50 |
article |
69 |
sanofi aventis
|
|
|
|
19 |
S4 |
p. iv266 |
article |
70 |
Satellite Symposia Schedule
|
|
|
|
19 |
S4 |
p. iv8 |
article |
71 |
session 14 – biological treatments
|
|
|
|
19 |
S4 |
p. iv129-iv130 |
article |
72 |
session 3 – biology and novel rational therapeutic targets in DLBCL
|
|
|
|
19 |
S4 |
p. iv97-iv98 |
article |
73 |
session 4 – diffuse large B-cell lymphoma
|
|
|
|
19 |
S4 |
p. iv99-iv100 |
article |
74 |
session 6 – extranodal lymphoma
|
|
|
|
19 |
S4 |
p. iv103-iv104 |
article |
75 |
session 5 – follicular lymphoma/CLL
|
|
|
|
19 |
S4 |
p. iv101-iv102 |
article |
76 |
session 12 – hodgkin's lymphoma
|
|
|
|
19 |
S4 |
p. iv120-iv121 |
article |
77 |
session 2 – mantle cell lymphoma
|
|
|
|
19 |
S4 |
p. iv85-iv86 |
article |
78 |
session 9 – micro-RNA in lymphoid malignancies
|
|
|
|
19 |
S4 |
p. iv117 |
article |
79 |
session 13 – new drugs
|
|
|
|
19 |
S4 |
p. iv127-iv128 |
article |
80 |
session 7 – pathology and clinical/pathological correlations
|
|
|
|
19 |
S4 |
p. iv105-iv107 |
article |
81 |
session 8 – pediatric lymphoma
|
|
|
|
19 |
S4 |
p. iv108-iv110 |
article |
82 |
session 10 – review lectures
|
|
|
|
19 |
S4 |
p. iv118 |
article |
83 |
session 11 – special topic: classifying lymphoma
|
|
|
|
19 |
S4 |
p. iv119 |
article |
84 |
session 1 – 50th anniversary of Burkitt lymphoma
|
|
|
|
19 |
S4 |
p. iv83-iv84 |
article |
85 |
subject index
|
|
|
|
19 |
S4 |
p. iv292-iv296 |
article |
86 |
summary of Conference Schedule
|
|
|
|
19 |
S4 |
p. iv6-iv7 |
article |
87 |
Table of Contents
|
|
|
|
19 |
S4 |
p. v |
article |
88 |
T-cell lymphoma
|
|
|
|
19 |
S4 |
p. iv153-iv157 |
article |
89 |
T-cell lymphoma
|
|
|
|
19 |
S4 |
p. iv230-iv232 |
article |
90 |
Title Page
|
|
|
|
19 |
S4 |
p. ii |
article |
91 |
transplantation
|
|
|
|
19 |
S4 |
p. iv239-iv242 |
article |
92 |
Treatment of lymphocyte-predominant Hodgkin lymphoma
|
Engert, A. |
|
|
19 |
S4 |
p. iv45-iv46 |
article |
93 |
treatment toxicity
|
|
|
|
19 |
S4 |
p. iv244-iv247 |
article |
94 |
Update on T-cell lymphoma
|
Vose, J.M. |
|
|
19 |
S4 |
p. iv74-iv76 |
article |